Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
INCY Incyte Corporation daily Stock Chart
INCY [NASD]
Incyte Corporation
Healthcare | Biotechnology | USA
statements
IndexS&P 500 P/E38.28 EPS (ttm)2.05 Insider Own0.40% Shs Outstand215.77M Perf Week13.96%
Market Cap16.96B Forward P/E19.84 EPS next Y3.96 Insider Trans-17.95% Shs Float215.35M Perf Month-0.03%
Income446.90M PEG1.20 EPS next Q0.63 Inst Own94.80% Short Float2.30% Perf Quarter0.89%
Sales2.16B P/S7.85 EPS this Y304.40% Inst Trans0.15% Short Ratio2.55 Perf Half Y4.95%
Book/sh12.04 P/B6.53 EPS next Y26.50% ROA14.50% Target Price90.73 Perf Year-5.56%
Cash/sh9.81 P/C8.01 EPS next 5Y31.94% ROE19.10% 52W Range62.48 - 96.79 Perf YTD-10.00%
Dividend- P/FCF26.81 EPS past 5Y55.60% ROI13.70% 52W High-18.80% Beta0.76
Dividend %- Quick Ratio4.80 Sales past 5Y33.40% Gross Margin95.70% 52W Low25.78% ATR4.25
Employees1456 Current Ratio4.80 Sales Q/Q9.70% Oper. Margin18.60% RSI (14)59.49 Volatility4.47% 6.66%
OptionableYes Debt/Eq0.02 EPS Q/Q58.90% Profit Margin20.70% Rel Volume1.14 Prev Close77.07
ShortableYes LT Debt/Eq0.01 EarningsMay 14 BMO Payout0.00% Avg Volume1.94M Price78.59
Recom2.20 SMA2010.97% SMA505.41% SMA200-2.76% Volume2,210,597 Change1.97%
Apr-01-20Upgrade Morgan Stanley Equal-Weight → Overweight $83 → $90
Mar-24-20Resumed William Blair Outperform
Mar-13-20Upgrade BofA/Merrill Neutral → Buy $83
Feb-04-20Resumed BofA/Merrill Neutral $82
Jan-03-20Reiterated BMO Capital Markets Market Perform $85 → $74
Jan-03-20Downgrade Mizuho Buy → Neutral $98 → $79
Jan-02-20Downgrade Guggenheim Buy → Neutral
Oct-03-19Initiated Mizuho Buy $95
Sep-12-19Initiated BMO Capital Markets Market Perform
Sep-05-19Upgrade Oppenheimer Perform → Outperform $100
Sep-05-19Upgrade JMP Securities Mkt Perform → Mkt Outperform $107
Sep-05-19Resumed Morgan Stanley Equal-Weight $82 → $87
May-21-19Initiated Credit Suisse Neutral $75
May-03-19Downgrade Barclays Overweight → Equal Weight $90 → $82
Apr-11-19Initiated Stifel Hold $82
Apr-03-19Downgrade RBC Capital Mkts Outperform → Sector Perform $89
Jan-24-19Upgrade William Blair Mkt Perform → Outperform
Jan-24-19Upgrade Gabelli & Co Hold → Buy $105
Jan-16-19Downgrade UBS Buy → Neutral
Jan-03-19Upgrade Guggenheim Neutral → Buy
Apr-05-20 08:00AM  Incyte Announces First Presentation of Phase 3 Data from the TRuE-AD Program of Ruxolitinib Cream at the Revolutionizing Atopic Dermatitis Virtual Symposium Business Wire
Apr-03-20 08:28PM  A Simple Blood Test May Be the Answer to Getting America Back to Work Barrons.com
10:55AM  Wilmington-based Incyte looking to repurpose flagship drug as COVID-19 treatment American City Business Journals
10:51AM  Pharma Coronavirus Efforts Continue, Amgen & Incyte Join In Zacks
10:16AM  Novartis Enlists Bone Marrow Cancer Drug in Fight Against Covid-19 TheStreet.com
10:13AM  A Cancer Drug From Incyte and Novartis Is Latest Potential Weapon Against Covid-19 Barrons.com
09:48AM  Incyte to Evaluate Lead Drug Jakafi for COVID-19 Infection Zacks
07:36AM  The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO Benzinga
03:32AM  Novartis, Incyte join repurposing wave to give Jakavi a trial run in COVID-19 Reuters
02:39AM  RPT-Novartis, Incyte join repurposing wave to give Jakavi a trial run in COVID-19 Reuters
02:36AM  Novartis, Incyte join repurposing wave to give Jakavi a trial run in COVID-19 Reuters
Apr-02-20 05:05PM  Incyte Announces Plans to Initiate a Phase 3 Clinical Trial of Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Cytokine Storm Business Wire
10:00AM  These 3 Biotech Stocks Are Outperforming Their Peers Here's Why Investor's Business Daily
Apr-01-20 01:54PM  Cancer startup raises $125M for Keytruda combo drug trial American City Business Journals
Mar-26-20 02:53PM  The Top 10 Biotechnology Companies Investopedia
08:00AM  Incyte Names New Member to Its Board of Directors Business Wire
Mar-24-20 07:30AM  Data from Phase 3 TRuE-AD Trials of Ruxolitinib Cream in Atopic Dermatitis to be Presented at the 2020 Revolutionizing Atopic Dermatitis Virtual Conference Business Wire +6.73%
Mar-17-20 08:08AM  Don't Sell Incyte Corporation (NASDAQ:INCY) Before You Read This Simply Wall St.
Mar-16-20 06:45AM  Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata PR Newswire
Mar-14-20 11:30AM  Incyte (INCY) Down 5.4% Since Last Earnings Report: Can It Rebound? Zacks
Mar-11-20 09:23PM  Hedge Funds Started Buying Incyte Corporation (INCY) Too Early Insider Monkey
Mar-10-20 03:12PM  Incyte Joins Elite List Of Stocks With 95-Plus Composite Rating Investor's Business Daily
Mar-05-20 01:11PM  Incyte approval triggers $750M payment for drug collaboration American City Business Journals
Mar-04-20 09:55AM  Biotech Stock Roundup: GILD to Buy Forty Seven, Pipeline Updates From BIIB & More Zacks
Mar-02-20 02:45PM  World Markets Rebound on Monday GuruFocus.com
Feb-28-20 03:06PM  Financial Markets Plunge on Coronavirus Outbreak GuruFocus.com
Feb-27-20 09:00AM  Incyte Partners with Artist and Patient J.G. Jones to Raise Awareness for Myeloproliferative Neoplasms (MPNs) Business Wire
08:42AM  The Zacks Analyst Blog Highlights: Moderna, Incyte, Heron Therapeutics and NGM Biopharmaceuticals Zacks
Feb-26-20 04:42PM  Biotech Stock Roundup: MRNA Surges, Pipeline Updates from INCY, HRTX & NGM Bio Zacks
Feb-19-20 09:21AM  Biotech Stock Roundup: INCY's Solid Q4 Results, EPZM & SGEN's Pipeline Updates Zacks
09:00AM  Incyte Announces Launch of the Incyte Ingenuity Award Program to Recognize Innovation Within the GVHD Community Business Wire
07:30AM  Incyte Announces Positive Topline Results From Phase 3 TRuE-AD Program Evaluating Ruxolitinib Cream in Patients With Atopic Dermatitis Business Wire
Feb-18-20 05:22PM  Frank Sands' Firm Sells 4 Stocks in 4th Quarter GuruFocus.com
Feb-14-20 09:53AM  Stock Market News for Feb 14, 2020 Zacks
Feb-13-20 11:31PM  Edited Transcript of INCY earnings conference call or presentation 13-Feb-20 1:00pm GMT Thomson Reuters StreetEvents
04:15PM  How A Blockbuster Drug Helped This Biotech Stock Top Estimates Investor's Business Daily
10:24AM  Incyte (INCY) Q4 Earnings Top Estimates on Solid Jakafi Sales Zacks
09:00AM  Incyte Stock Is Rising After the Drug Company Reports a Solid Quarter and Guidance Barrons.com
08:35AM  Incyte (INCY) Q4 Earnings and Revenues Beat Estimates Zacks
07:00AM  Incyte Reports 2019 Fourth Quarter and Year-End Financial Results and Provides 2020 Financial Guidance and Updates on Key Clinical Programs Business Wire
02:03AM  Incyte Earnings, Revenue Beat in Q4 Investing.com
Feb-11-20 09:04AM  Incyte's (INCY) Capmatinib NDA Gets Priority Review From FDA Zacks
08:00AM  Incyte to Present at Upcoming Investor Conference Business Wire
01:17AM  Incyte Announces Acceptance and Priority Review of NDA for Capmatinib for Advanced Non-Small Cell Lung Cancer Business Wire
Feb-07-20 09:44AM  Incyte (INCY) to Report Q4 Earnings: What's in the Cards? Zacks
Feb-06-20 09:09AM  Incyte (NASDAQ:INCY) Has A Rock Solid Balance Sheet Simply Wall St.
Jan-31-20 04:53PM  Lilly's Olumiant Succeeds in Another Late-Stage Eczema Study Zacks
Jan-30-20 06:15AM  Lilly and Incyte Announce Positive Top-Line Results from the North American (BREEZE-AD5) Phase 3 Study of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate to Severe Atopic Dermatitis PR Newswire
Jan-29-20 11:11AM  Incyte's Phase III Atopic Dermatitis Study Meets Primary Goal Zacks
09:59AM  Biotech Stock Roundup: EPZM Drug Gets FDA Nod, XLRN & HEPA Surge on Study Data Zacks
Jan-28-20 05:50PM  Incyte (INCY) Gains But Lags Market: What You Should Know Zacks
04:03PM  Could An Eczema Treatment Pull Incyte Stock Out Of Its Downtrend? Investor's Business Daily
01:04PM  Top Health Care Stocks for February 2020 Investopedia
10:31AM  Lilly's Olumiant Meets Primary Goal in Dermatitis Study Zacks
07:46AM  Incyte's skin disease drug meets main goal in late-stage study Reuters
07:30AM  Incyte Announces that the TRuE-AD2 Pivotal Trial of Ruxolitinib Cream Met its Primary Endpoint in Patients with Atopic Dermatitis Business Wire
Jan-27-20 09:08AM  3 Biotech Stocks Nearing Support Investopedia
06:45AM  Lilly and Incyte Announce Top-Line Results from Phase 3 Study (BREEZE-AD4) of Oral Selective JAK Inhibitor Baricitinib in Combination with Topical Corticosteroids in Patients with Moderate to Severe Atopic Dermatitis Not Controlled with Cyclosporine PR Newswire
Jan-23-20 08:00AM  Incyte to Report Fourth Quarter and Year-End Financial Results Business Wire
Jan-15-20 10:24AM  Democrats Called for Cuts to Drug Prices at the Debate. The Pharma Industry Says Its Trying. Barrons.com
Jan-13-20 04:58PM  Incyte makes $750M upfront payment for rights to German cancer drug American City Business Journals
Jan-09-20 02:50PM  Top Biotech Stocks for Q1 2020 Investopedia
Jan-08-20 05:50PM  Incyte (INCY) Stock Sinks As Market Gains: What You Should Know Zacks
11:26AM  Incyte's Application for Pemigatinib Gets EMA's Validation Zacks
10:07AM  Biotech Stock Roundup: Updates From INCY & EXEL, APLS & LIFE Surge on Positive Data Zacks
Jan-07-20 06:00AM  Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Pemigatinib in Patients with Cholangiocarcinoma Business Wire
Jan-06-20 10:06AM  Company News For Jan 6, 2020 Zacks
Jan-04-20 09:05AM  Dow logs worst day in 4 weeks, amid rising Middle East tensions and weak U.S. factory data MarketWatch
Jan-03-20 04:21PM  Stock Market Trims Losses After U.S. Airstrike Sends Stocks Tumbling; Apple, Incyte, Tesla Key Movers Investor's Business Daily -9.39%
04:15PM  Stock Market Rally Continues Into 2020; Tesla, Lockheed Soar, Incyte Plunges: Weekly Review Investor's Business Daily
04:13PM  Incyte Stock Pummeled As Late-Stage Failure Casts Doubt On Pipeline Investor's Business Daily
10:18AM  Oil Is Surging, Gold Is Up, and the Dow Is Dropping After U.S. Airstrike Barrons.com
10:01AM  Incyte's (INCY) Itacitinib Fails in Late-Stage GVHD Study Zacks
09:33AM  Incyte Stock Is Tanking After a Disappointing Study. Analysts Are Mixed on How Bad the News Really Is. Barrons.com
08:07AM  Dow Jones Futures Plunge As U.S. Airstrike Kills Top Iranian General After 2020 Stock Market Rally Starts Strong Investor's Business Daily
07:55AM  The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger Benzinga
04:41AM  Incyte Downgraded After Graft vs. Host Disease Drug Fails Trial TheStreet.com
02:11AM  U.S. Kills Iranian General, Oil Prices Surge, FOMC to Release Minutes - 5 Things You Must Know Friday TheStreet.com
01:20AM  U.S. Kills Iranian General, Oil Prices Surge, FOMC to Release Minutes - 5 Things You Must Know Friday TheStreet.com
Jan-02-20 05:29PM  Leading Biotech Stock Crashes After Promising Drug Fails Late-Stage Test Investor's Business Daily
04:40PM  Incyte stock slammed after study fails to hit goal MarketWatch
04:30PM  Incyte Announces Results of Phase 3 Study of Itacitinib in Patients with Treatment-Naïve Acute Graft-Versus-Host Disease Business Wire
12:38PM  Incyte Shares Fall in After-Hours Trading on Drug Trial Disappointment TheStreet.com
Jan-01-20 02:16PM  How Good Is Incyte Corporation (NASDAQ:INCY), When It Comes To ROE? Simply Wall St.
Dec-29-19 09:40PM  Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus Benzinga
Dec-27-19 05:50PM  Incyte (INCY) Stock Moves -0.44%: What You Should Know Zacks
09:29AM  Incyte Looking At 10-day Line Support Investor's Business Daily Video
Dec-26-19 10:43AM  How Did Incyte Corporation (INCY) Compare Against Top Hedge Fund Stocks in 2019? Insider Monkey
09:13AM  Incyte (INCY) Surges 44% YTD on Jakafi's Strong Performance Zacks
Dec-24-19 11:30AM  Has Incyte (INCY) Outpaced Other Medical Stocks This Year? Zacks
Dec-20-19 05:45PM  Incyte (INCY) Stock Sinks As Market Gains: What You Should Know Zacks
Dec-19-19 10:18AM  Biotech Stock Outlook: M&A Activity Retains Growth Streak Zacks
07:30AM  Incyte Names New Member to Its Board of Directors Business Wire
Dec-18-19 05:00AM  Incyte Gets Priority Review for Cancer Treatment MoneyShow
Dec-16-19 12:00PM  Here's Why Momentum Investors Will Love Incyte (INCY) Zacks
Dec-10-19 04:36PM  Stock Market Claws Back From Early 105-Point Dow Loss, But Still Ends In Red; Apple, Nike Continue Bullish Moves Investor's Business Daily
01:23PM  See 33 Top Stocks Up 32.4% To 145% Year To Date Investor's Business Daily
05:13AM  Moving Average Crossover Alert: Incyte Zacks
Dec-05-19 08:00AM  Incyte to Present at Upcoming Investor Conference Business Wire
Dec-04-19 10:02AM  Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More Zacks
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naive chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. Further, it is involved in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; MorphoSys AG; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; and Zai Lab Limited. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SWAIN PAULA JEVP, Human ResourcesMar 31Option Exercise64.552,329150,33750,132Apr 02 05:32 PM
SWAIN PAULA JEVP, Human ResourcesMar 31Sale71.442,329166,38448,493Apr 02 05:32 PM
Pasquale Maria EEVP & General CounselMar 11Option Exercise65.361288,36626,096Mar 13 04:18 PM
BROOKE PAUL ADirectorFeb 21Option Exercise13.3420,000266,800221,584Feb 25 04:39 PM
SWAIN PAULA JEVP, Human ResourcesFeb 19Option Exercise64.552,500161,37550,993Feb 21 04:11 PM
SWAIN PAULA JEVP, Human ResourcesFeb 19Sale80.002,500200,00048,493Feb 21 04:11 PM
Pasquale Maria EEVP & General CounselFeb 10Option Exercise65.361278,30119,087Feb 12 05:00 PM
Wenqing YaoEVP, Head of Discovery ChemFeb 05Option Exercise18.3217,542321,369112,850Feb 07 04:48 PM
Wenqing YaoEVP, Head of Discovery ChemFeb 05Sale75.9717,5421,332,66695,308Feb 07 04:48 PM
SWAIN PAULA JEVP, Human ResourcesJan 15Option Exercise64.552,500161,37544,112Jan 17 04:20 PM
SWAIN PAULA JEVP, Human ResourcesJan 15Sale81.122,500202,80041,612Jan 17 04:20 PM
Pasquale Maria EEVP & General CounselJan 10Option Exercise65.361278,30118,960Jan 14 04:54 PM
SWAIN PAULA JEVP, Human ResourcesDec 16Option Exercise64.552,500161,37544,112Dec 18 04:59 PM
SWAIN PAULA JEVP, Human ResourcesDec 16Sale91.612,500229,02541,612Dec 18 04:59 PM
Pasquale Maria EEVP & General CounselDec 12Option Exercise65.36775,03318,833Dec 16 04:35 PM
Flannelly Barry PEVP & General Manager USDec 02Option Exercise73.216,582481,86823,561Dec 03 04:20 PM
Iyengar Vijay KEVP GPS, BD, & LicensingDec 02Option Exercise72.867,366536,68724,975Dec 03 04:25 PM
Wenqing YaoEVP, Head of Discovery ChemDec 02Option Exercise18.3216,835308,417112,143Dec 03 04:32 PM
Iyengar Vijay KEVP GPS, BD, & LicensingDec 02Sale95.007,366699,77017,609Dec 03 04:25 PM
Wenqing YaoEVP, Head of Discovery ChemDec 02Sale95.0016,8351,599,32595,308Dec 03 04:32 PM
Flannelly Barry PEVP & General Manager USDec 02Sale95.006,582625,29016,979Dec 03 04:20 PM
Flannelly Barry PEVP & General Manager USNov 29Option Exercise73.2160043,92617,579Dec 03 04:20 PM
Wenqing YaoEVP, Head of Discovery ChemNov 29Option Exercise18.323,16557,98398,473Dec 03 04:32 PM
Iyengar Vijay KEVP GPS, BD, & LicensingNov 29Option Exercise72.8650036,43018,109Dec 03 04:25 PM
Wenqing YaoEVP, Head of Discovery ChemNov 29Sale95.003,165300,67595,308Dec 03 04:32 PM
Iyengar Vijay KEVP GPS, BD, & LicensingNov 29Sale95.0050047,50017,609Dec 03 04:25 PM
Flannelly Barry PEVP & General Manager USNov 29Sale95.0060057,00016,979Dec 03 04:20 PM
Trower PaulPrincipal Accounting OfficerNov 25Option Exercise18.3215,000274,80032,306Nov 26 04:06 PM
Wenqing YaoEVP, Head of Discovery ChemNov 25Option Exercise18.3215,000274,800110,308Nov 26 04:11 PM
Flannelly Barry PEVP & General Manager USNov 25Option Exercise48.442,142103,75818,699Nov 26 04:31 PM
Flannelly Barry PEVP & General Manager USNov 25Sale90.002,142192,78016,979Nov 26 04:31 PM
Wenqing YaoEVP, Head of Discovery ChemNov 25Sale90.0015,0001,350,00095,308Nov 26 04:11 PM
Trower PaulPrincipal Accounting OfficerNov 25Sale90.0015,0001,350,00017,306Nov 26 04:06 PM
SWAIN PAULA JEVP, Human ResourcesNov 15Option Exercise64.552,500161,37544,112Nov 19 05:45 PM
SWAIN PAULA JEVP, Human ResourcesNov 15Sale86.462,500216,15041,612Nov 19 05:45 PM
Pasquale Maria EEVP & General CounselNov 13Option Exercise65.36764,96718,756Nov 14 05:32 PM
DIXON WENDY LDirectorNov 08Option Exercise12.4641,218513,57635,224Nov 08 05:25 PM
DIXON WENDY LDirectorNov 08Sale83.8741,2183,456,95412,340Nov 08 05:25 PM
DIXON WENDY LDirectorNov 07Option Exercise12.461,54019,18813,880Nov 08 05:25 PM
DIXON WENDY LDirectorNov 07Sale83.601,540128,74412,340Nov 08 05:25 PM
DIXON WENDY LDirectorNov 06Option Exercise12.4610,576131,77722,916Nov 08 05:25 PM
DIXON WENDY LDirectorNov 06Sale84.1610,576890,07612,340Nov 08 05:25 PM
Trower PaulPrincipal Accounting OfficerNov 01Option Exercise18.328,500155,72025,806Nov 05 04:33 PM
Wenqing YaoEVP, Head of Discovery ChemNov 01Option Exercise18.327,960145,827103,268Nov 05 05:23 PM
Trower PaulPrincipal Accounting OfficerNov 01Sale85.008,500722,50017,306Nov 05 04:33 PM
Wenqing YaoEVP, Head of Discovery ChemNov 01Sale85.007,960676,60095,308Nov 05 05:23 PM
Trower PaulPrincipal Accounting OfficerOct 29Option Exercise18.3216,500302,28025,705Oct 31 04:07 PM
Wenqing YaoEVP, Head of Discovery ChemOct 29Option Exercise18.322,04037,37347,348Oct 31 04:10 PM
Wenqing YaoEVP, Head of Discovery ChemOct 29Sale85.002,040173,40045,308Oct 31 04:10 PM
Trower PaulPrincipal Accounting OfficerOct 29Sale80.4516,5001,327,50017,306Oct 31 04:07 PM
Iyengar Vijay KEVP GPS, BD, & LicensingOct 29Sale85.0093079,05017,609Oct 31 04:00 PM
SWAIN PAULA JEVP, Human ResourcesOct 22Option Exercise64.552,500161,37544,112Oct 24 06:52 PM
SWAIN PAULA JEVP, Human ResourcesOct 22Sale80.002,500200,00041,612Oct 24 06:52 PM
Pasquale Maria EEVP & General CounselOct 10Option Exercise65.36775,03318,680Oct 11 04:40 PM
SWAIN PAULA JEVP, Human ResourcesSep 18Option Exercise64.552,500161,37544,112Sep 19 04:34 PM
SWAIN PAULA JEVP, Human ResourcesSep 18Sale80.002,500200,00041,612Sep 19 04:34 PM
Flannelly Barry PEVP & General Manager USSep 17Sale77.712,491193,57616,757Sep 19 04:30 PM
Pasquale Maria EEVP & General CounselSep 09Option Exercise65.36764,96718,603Sep 11 04:29 PM
SWAIN PAULA JEVP, Human ResourcesAug 15Option Exercise64.552,500161,37544,112Aug 19 04:21 PM
SWAIN PAULA JEVP, Human ResourcesAug 15Sale80.962,500202,40041,612Aug 19 04:21 PM
Pasquale Maria EEVP & General CounselAug 09Option Exercise65.361,22379,93518,527Aug 13 04:35 PM
FRIEDMAN PAUL ADirectorAug 06Option Exercise18.3277,9341,427,751333,465Aug 06 06:45 PM
FRIEDMAN PAUL ADirectorAug 06Sale82.2077,9346,406,175255,531Aug 06 06:45 PM
FRIEDMAN PAUL ADirectorAug 02Option Exercise18.3222,066404,249277,597Aug 06 06:45 PM
FRIEDMAN PAUL ADirectorAug 02Sale84.4122,0661,862,591255,531Aug 06 06:45 PM
BIENAIME JEAN JACQUESDirectorAug 02Sale84.7337731,9437,055Aug 05 04:36 PM
BIENAIME JEAN JACQUESDirectorAug 01Sale85.161,347114,7117,432Aug 05 04:36 PM
Flannelly Barry PEVP & General Manager USJul 17Sale79.9195976,63419,248Jul 18 06:13 PM
SWAIN PAULA JEVP, Human ResourcesJul 15Option Exercise64.552,500161,37544,751Jul 16 04:48 PM
SWAIN PAULA JEVP, Human ResourcesJul 15Sale80.002,500200,00042,251Jul 16 04:48 PM
Stein Steven HEVP & Chief Medical OfficerJun 24Sale87.968,357735,08210,805Jun 25 05:46 PM
SWAIN PAULA JEVP, Human ResourcesJun 17Option Exercise64.552,500161,37539,013Jun 18 05:26 PM
SWAIN PAULA JEVP, Human ResourcesJun 17Sale80.002,500200,00036,513Jun 18 05:26 PM
open in yahoo | open in reuters | open in google